Orchard Therapeutics Ltd has obtained rights to technology developed by the French research institution Généthon to continue development of a new gene therapy for the immune deficiency, X-linked chronic granulomatous disease. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
